By Scott Miller
Published Jan. 15, 2013
Terms were not released.
Selah CEO Michael Bolick said the acquisition will serve as a catalyst for expansion in Columbia and as a gateway to partnerships with the University of South Carolina. No details about expanding in Columbia could be released. The acquisition also provides Selah a connection to support oncology and other medical research at the new USC School of Medicine at the Greenville Memorial Hospital campus, Bolick said.
EnGenCore, established through a public-private partnership, uses sequencing equipment to map the genomic makeup of DNA samples for medical research. The company’s clients have included researchers at Cornell, Emory, Harvard and Yale universities, as well as Pfizer, Bristol-Myers Squibb and the U.S. Department of Energy. It also has clients in numerous foreign countries, including Mexico, Canada, Brazil, Saudi Arabia and China.
The EnGenCore lab at Innovista was set up in 2007 with $2 million appropriated by the General Assembly.
Nexus Medical Partners, SCRA Technology Ventures’ Stage 2 Affiliate, SC Launch and the University of South Carolina’s Office of Foundations supported Selah’s transaction. Details were not released.
Selah, which was Lab21 until local management bought out the company last week, provides advanced diagnostics testing services for patient services and clinical research. Its main office and laboratory is in the Next Innovation Center in downtown Greenville. The company also has a clinical lab at Greenville Hospital System’s Institute for Translational Oncology Research.
“I am very appreciative of the support that USC Environmental Health Sciences, the Darla Moore School of Business, SC Launch and the FastTrac TechVenture programs provided me when I founded EnGenCore,” EnGenCore’s John Busch said in a news release. “This exciting growth opportunity can be directly attributed to these folks and our state leaders who set out years ago (to) help build (a) robust support network for life science entrepreneurs. Today, South Carolina’s biotechnology sector is emerging as (a) hotbed of exciting developments in the life sciences generally and personalized medicine in particular. I am thrilled by this opportunity to join forces as a co-founder of Selah Genomics.”